Who
Vincent Vultaggio
PAO and PFO
Company insider
Files Form 4 as: PAO and PFO, Zentalis Pharmaceuticals.
In numbers
- Trades disclosed
- 16
- Buys
- 0
- Sells
- 7
- Bought
- $0
- Sold
- $220K
- Companies
- 1
- Companies where not an officer
- 0
- First trade
- 4 Oct 2024
- Last trade
- 10 Feb 2026
- Last filed
- 10 Feb 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 10 Feb 2026filed 10 Feb 2026 | ZNTL Zentalis PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $17K6,894 at $2.42 | filing |
| 10 Feb 2026filed 10 Feb 2026 | ZNTL Zentalis PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $17K6,894 at $2.42 | filing |
| 9 Feb 2026filed 10 Feb 2026 | ZNTL Zentalis PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $8,0863,379 at $2.39 | filing |
| 9 Feb 2026filed 10 Feb 2026 | ZNTL Zentalis PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $8,0763,379 at $2.39 | filing |
| 6 Feb 2026filed 10 Feb 2026 | ZNTL Zentalis PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $73K29,951 at $2.43 | filing |
| 6 Feb 2026filed 10 Feb 2026 | ZNTL Zentalis PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $73K29,951 at $2.43 | filing |
| 3 Feb 2026filed 4 Feb 2026 | ZNTL Zentalis PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $1,398556 at $2.52 | filing |
| 3 Feb 2026filed 4 Feb 2026 | ZNTL Zentalis PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $1,401556 at $2.52 | filing |
| 2 Feb 2026filed 4 Feb 2026 | ZNTL Zentalis PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $6,4772,540 at $2.55 | filing |
| 2 Feb 2026filed 4 Feb 2026 | ZNTL Zentalis PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $6,4772,540 at $2.55 | filing |
| 8 Jan 2026filed 9 Jan 2026 | ZNTL Zentalis Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —100,000 at $0.00 | filing |
| 8 Jan 2026filed 9 Jan 2026 | ZNTL Zentalis Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —100,000 at $0.00 | filing |
| 3 Feb 2025filed 5 Feb 2025 | ZNTL Zentalis Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —35,633 at $0.00 | filing |
| 3 Feb 2025filed 5 Feb 2025 | ZNTL Zentalis PharmaceuticalsBiotechnology | SEC FORM 4 Code A | —158,586 at $0.00 | filing |
| 3 Feb 2025filed 5 Feb 2025 | ZNTL Zentalis PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $4,4722,615 at $1.71 | filing |
| 4 Oct 2024filed 4 Oct 2024 | ZNTL Zentalis PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $5,0981,603 at $3.18 | filing |
News
Zentalis Pharmaceuticals Announces First Overall Survival Data for Azenosertib from DENALI Part 1b Published in ESMO Congress 2026 AbstractZNTL · manilatimes.net · 18 Oct 2026
0 headlines in the last 90 days name Vincent Vultaggio; 1 article from the last 14 days about the 1 company they traded most, at most three about any one of them.